MediciNova Reports Phase 2 MN-001 Results in Metabolic Disease
LA JOLLA, Calif. — September 28, 2026 MediciNova, Inc. reported topline results from the randomized, double-blind, placebo-controlled MN-001-NATG-202 Phase...
Biopharmaceutical
Advertisement
Roivant and Pulmovant to Unveil Topline Mosliciguat Results in PH-ILD
Basel, Switzerland / London, UK / New York, NY — September 6, 2026 Roivant and Pulmovant announced that topline...
Persica Strengthens PP353 Case in Vertebrogenic Back Pain
London, UK — September 4, 2026 Persica Pharmaceuticals Limited announced the publication of new antibiotic exposure-response analyses supporting the...
Clearmind Advances CMND-100 Into Phase IIa Trial for Alcohol Use Disorder
Vancouver, Canada — September 1, 2026 Clearmind Medicine Inc. announced the initiation of Phase IIa development for CMND-100, its...
DualityBio and Genentech Partner on Next-Gen ADCs
SHANGHAI, CHINA, Aug 28, 2026 Duality Biotherapeutics, Inc. (DualityBio) has entered into a global collaboration and license agreement with...
Advertisements
Sagimet Advances Denifanstat Acne Phase 3 Trial
FOSTER CITY, Calif. — August 25, 2026 Sagimet Biosciences announced that its AURORA Phase 3 clinical trial of denifanstat...
Quantum BioPharma Advances Lucid-MS Into Phase 2
Toronto, Canada — August 14, 2026 Quantum BioPharma Ltd. reported continued progress on its lead therapeutic program Lucid-MS, following...
Pharming Launches Joenja in Japan for APDS Patients
LEIDEN, Netherlands, August 13, 2026 Pharming Group N.V. announced the commercial launch of Joenja® (leniolisib) in Japan for adults...
Vaderis Therapeutics Advances Engasertib Into Phase 3
Basel, Switzerland & Lincolnshire, Illinois, August,11, 2026 Vaderis Therapeutics, a clinical-stage biopharmaceutical company focused on targeted therapies for rare...
CalciMedica Aligns With FDA on Auxora Phase 2b Trial
LA JOLLA, Calif., July 29, 2026 CalciMedica, Inc. has announced a significant regulatory milestone after reaching alignment with the...
Advertisement
